|Bid||3.5000 x 800|
|Ask||4.8900 x 1300|
|Day's Range||3.5400 - 3.8590|
|52 Week Range||1.8200 - 6.2900|
|Beta (5Y Monthly)||2.43|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 06, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||9.00|
GlycoMimetics, Inc. (Nasdaq: GLYC), today announces that CEO Rachel King plans to present an overview of the company at the upcoming Stifel 2020 Virtual Healthcare Conference on Tuesday, November 17 and the Jefferies Virtual London Healthcare Conference on Thursday, November 19. Both presentations will be available on the Company’s website, under the Investors tab. Details are as follows:
Good Morning and thank you all for joining GlycoMimetics corporate update conference call. Brian will provide an overview of the company's financial position and we'll then open the call for Q&A. Our Co-Founder and Chief Scientific Officer, Dr. John Magnani will join us in the Q&A to address your questions on the emerging preclinical data.
GlycoMimetics, Inc. (Nasdaq: GLYC) today reported its financial results for the third quarter ended September 30, 2020, and highlighted recent company events. Cash and cash equivalents at September 30, 2020 were $142.9 million.